Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.
A study testing the all oral combination of ixazomib, cyclophosphamide, and dexamethasone showed that patients with newly diagnosed multiple myeloma responded well to the experimental treatment regimen.
Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
The FDA granted approval to ofatumumab for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial remission after two or more lines of prior therapy.